Jackhammer(hypercontractile) esophagus presents with dysphagia and chest pain. Current treatments are limited. We describe a 60-year-old man who presented with dysphagia, chest pain and heartburn for a period of 1 yea...Jackhammer(hypercontractile) esophagus presents with dysphagia and chest pain. Current treatments are limited. We describe a 60-year-old man who presented with dysphagia, chest pain and heartburn for a period of 1 year. His workup showed Barrett's esophagus on endoscopy and high-resolution manometry demonstrated jackhammer esophagus with esophagogastric junction outflow obstruction. The patient was treated with proton pump inhibitor and nifedipine but without resolution of his symptoms. He was followed up to assess the efficacy of treatment with deanxit(flupentixol + melitracen). Dysphagia and chest pain resolved during the therapeutic trial and efficacy was maintained on maintenance treatment without troublesome side effects.展开更多
Objective: To explore the effect of zopiclone combined with Deanxit on cytokines and neurotransmitters in patients with poststroke depression. Methods: A total of 78 patients with poststroke depression who were treate...Objective: To explore the effect of zopiclone combined with Deanxit on cytokines and neurotransmitters in patients with poststroke depression. Methods: A total of 78 patients with poststroke depression who were treated in Zaozhuang Mining Group Dongjiao Hospital between January 2015 and February 2017 were divided into control group (n=41, receiving conventional Deanxit therapy) and zopiclone group (n=37, receiving zopiclone combined with Deanxit therapy). The differences in serum nerve injury marker, inflammatory cytokine and monoamine neurotransmitter levels were compared between the two groups before treatment and after 12 weeks of treatment. Results: Before treatment, serum levels of nerve injury markers, inflammatory cytokines and monoamine neurotransmitters were not significantly different between the two groups. After 12 weeks of treatment, serum nerve injury markers NSE and S100B levels of zopiclone group were lower than those of control group whereas BDNF level was higher than that of control group;serum inflammatory cytokines IL-1, IL-2, IL-23 and TNF-α levels of zopiclone group were lower than those of control group;serum monoamine neurotransmitters NE, 5-HT and DA levels of zopiclone group were higher than those of control group. Conclusion: Zopiclone combined with Deanxit therapy can effectively optimize the neurological function, reduce the inflammatory response and increase the secretion of monoamine neurotransmitters in patients with poststroke depression.展开更多
Objective： To observe the clinical efficacy of tuina in treating depression. Method： Eighty depression cases that conformed to the inclusive criteria were randomized into tuina and Deanxit group, with 40 cases in ea...Objective： To observe the clinical efficacy of tuina in treating depression. Method： Eighty depression cases that conformed to the inclusive criteria were randomized into tuina and Deanxit group, with 40 cases in each group. Tuina manipulations were adopted for cases in the tuina group, 30 min for each treatment. While 2 Deanxit tablets were adopted for cases in the Deanxit group, twice a day. The clinical efficacy of the two groups was evaluated by using Hamilton Rating Scale for Depression （HAMD） before treatment and the 2nd, 4ta and 6th weeks after. In addition, the Treatment Emergent Symptom Scale （TESS） was adopted to evaluate the adverse reactions in the two groups. Result： Both tuina and Deanxit can help to relieve the symptoms of depression patients. The effective rate of tuina and Deanxit were 72.5% and 70.0% respectively. However, there were no adverse reactions in tuina group, while 12.5% of adverse reaction rate occurred in the Deanxit group. Conclusion： Tuina can definitely benefit patients with depression and cause no adverse reactions.展开更多
文摘Jackhammer(hypercontractile) esophagus presents with dysphagia and chest pain. Current treatments are limited. We describe a 60-year-old man who presented with dysphagia, chest pain and heartburn for a period of 1 year. His workup showed Barrett's esophagus on endoscopy and high-resolution manometry demonstrated jackhammer esophagus with esophagogastric junction outflow obstruction. The patient was treated with proton pump inhibitor and nifedipine but without resolution of his symptoms. He was followed up to assess the efficacy of treatment with deanxit(flupentixol + melitracen). Dysphagia and chest pain resolved during the therapeutic trial and efficacy was maintained on maintenance treatment without troublesome side effects.
基金Shandong Provincial Natural Science Foundation Project(Grant No.81471371).
文摘Objective: To explore the effect of zopiclone combined with Deanxit on cytokines and neurotransmitters in patients with poststroke depression. Methods: A total of 78 patients with poststroke depression who were treated in Zaozhuang Mining Group Dongjiao Hospital between January 2015 and February 2017 were divided into control group (n=41, receiving conventional Deanxit therapy) and zopiclone group (n=37, receiving zopiclone combined with Deanxit therapy). The differences in serum nerve injury marker, inflammatory cytokine and monoamine neurotransmitter levels were compared between the two groups before treatment and after 12 weeks of treatment. Results: Before treatment, serum levels of nerve injury markers, inflammatory cytokines and monoamine neurotransmitters were not significantly different between the two groups. After 12 weeks of treatment, serum nerve injury markers NSE and S100B levels of zopiclone group were lower than those of control group whereas BDNF level was higher than that of control group;serum inflammatory cytokines IL-1, IL-2, IL-23 and TNF-α levels of zopiclone group were lower than those of control group;serum monoamine neurotransmitters NE, 5-HT and DA levels of zopiclone group were higher than those of control group. Conclusion: Zopiclone combined with Deanxit therapy can effectively optimize the neurological function, reduce the inflammatory response and increase the secretion of monoamine neurotransmitters in patients with poststroke depression.
文摘Objective： To observe the clinical efficacy of tuina in treating depression. Method： Eighty depression cases that conformed to the inclusive criteria were randomized into tuina and Deanxit group, with 40 cases in each group. Tuina manipulations were adopted for cases in the tuina group, 30 min for each treatment. While 2 Deanxit tablets were adopted for cases in the Deanxit group, twice a day. The clinical efficacy of the two groups was evaluated by using Hamilton Rating Scale for Depression （HAMD） before treatment and the 2nd, 4ta and 6th weeks after. In addition, the Treatment Emergent Symptom Scale （TESS） was adopted to evaluate the adverse reactions in the two groups. Result： Both tuina and Deanxit can help to relieve the symptoms of depression patients. The effective rate of tuina and Deanxit were 72.5% and 70.0% respectively. However, there were no adverse reactions in tuina group, while 12.5% of adverse reaction rate occurred in the Deanxit group. Conclusion： Tuina can definitely benefit patients with depression and cause no adverse reactions.
